Research / 2021 / Article / Tab 3

Review Article

Low-Temperature Photothermal Therapy: Strategies and Applications

Table 3

Low-temperature PTT-involving synergistic therapies.

Therapeutic modality in combination with PTTAgents (except PTAs)PTAsReference

ChemotherapyDOXPEGGC shell[159]
HAGd-hybridized plasmonic Au-nanocomposites[160]
PVPRbxWO3 nanorods[162]
Low-temperature-sensitive liposomesGold nanoantennas[163]
PEGPDA and ICG[166]
Poly(acrylic acid-b-N-isopropylamide-b-acrylic acid)PPy[169]
Fe3+ carboxylate MOFs[173]
Meso-2,3-dimercaptosuccinic acidFe3O4[174]
Hydroxypropyl-β-cyclodextrin (HP-β-CD)Fe3O4/carbon NPs[175]
Periodic mesoporous organosilica NPsCuS[176]
CamptothecinHollow CuS NPs[161]
Paclitaxel and HSABlack phosphorus nanosheets[164]
SN38 and alendronatePDA[165]
DTX, PLGA, and PEGPPy[168]
Gemcitabine, 17-AAG, hollow mesoporous organosilica nanocapsule, and PEGICG[170]
DOX and cisplatinPDA[172]
Cisplatin and amphiphilic polymer containing Pt(IV) prodrugs and pendant iodidesIR780[177]

RT131I and PEGRGO[186]
PEGGd3+-doped WS2 nanoflakes[187]
PEGBi NPs[188]
HA and GABi2Se3 HNCs[189]

PDTPEG and HSP70 siRNAZr-FeP MOF nanoshuttles[194]
Ce6 and PEGMoS2 nanosheets[196]
HPPHBCCG nanodots[197]
Ce6Amino-rich red emissive CDs[198]
HMONs, BSA, PEG, and 17-AAGIrO2[199]
DTX, mPEG-PCL, PCL-g-PEI, and Lyp-1IR820[200]

SDTPVPTiH1.924 nanodots[202]

W18O49 nanorods[209]

Gas therapyBNN and Tween-20Bi2S3 NPs[214]
S-nitrosothiol, PES, and PEGAu@SiO2[215]

Gene therapyHSP-regulated gene plasmidsSemiconducting backbones[217]
Therapeutic plasmid DNA and PEIPB[218]
HSP-nuclease protein 9 (Cas9) plasmidsCationic polymer-coated Au nanorods[219]
Oncolytic AdsAuNRs[223]
BAG3-targeting siRNA oligomersAuNRs[225]

ImmunotherapyCSPG4-specific CAR T cellsICG[242]
aPD-L1, folic acid, and SNX-2112GO[255]
aPD-L1 and LG depotIR820[256]
siRNA against PD-L1, mPEG, and PEIBismuthene[257]
R848 and GCSPANI[262]
aPD-L1WO2.9-WSe2-PEG NPs[272]
FeOOH nanodots and STA-9090Cu-LDH[43]
Oxaliplatin and EGCGPCS nanomaterials[273]